Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
MARKSANS PHARMA. TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
MARKSANS PHARMA. Mar-23 |
TEVA PHARMA Dec-13 |
MARKSANS PHARMA./ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 74 | 3,481 | - | |
Low | Rs | 39 | 3,024 | - | |
Sales per share (Unadj.) | Rs | 40.9 | 1,997.6 | - | |
Earnings per share (Unadj.) | Rs | 5.9 | 124.8 | - | |
Cash flow per share (Unadj.) | Rs | 7.0 | 286.3 | - | |
Dividends per share (Unadj.) | Rs | 0.50 | 109.24 | - | |
Avg Dividend yield | % | 0.9 | 3.4 | 26.3% | |
Book value per share (Unadj.) | Rs | 38.5 | 2,219.0 | - | |
Shares outstanding (eoy) | m | 453.16 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.4 | 1.6 | 85.0% | |
Avg P/E ratio | x | 9.7 | 26.1 | 37.1% | |
P/CF ratio (eoy) | x | 8.1 | 11.4 | 71.1% | |
Price / Book Value ratio | x | 1.5 | 1.5 | 100.2% | |
Dividend payout | % | 8.5 | 87.5 | 9.8% | |
Avg Mkt Cap | Rs m | 25,631 | 2,757,874 | 0.9% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 2,394 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,690.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,354.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 18,521 | 1,693,984 | 1.1% | |
Other income | Rs m | 593 | 0 | - | |
Total revenues | Rs m | 19,115 | 1,693,984 | 1.1% | |
Gross profit | Rs m | 3,393 | 463,899 | 0.7% | |
Depreciation | Rs m | 519 | 136,926 | 0.4% | |
Interest | Rs m | 91 | 33,273 | 0.3% | |
Profit before tax | Rs m | 3,377 | 293,700 | 1.1% | |
Minority Interest | Rs m | 0 | 1,334 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,798 | -0.0% | |
Tax | Rs m | 723 | -3,586 | -20.2% | |
Profit after tax | Rs m | 2,653 | 105,822 | 2.5% | |
Gross profit margin | % | 18.3 | 27.4 | 66.9% | |
Effective tax rate | % | 21.4 | -1.2 | -1,754.6% | |
Net profit margin | % | 14.3 | 6.2 | 229.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 16,997 | 1,144,111 | 1.5% | |
Current liabilities | Rs m | 3,654 | 997,761 | 0.4% | |
Net working cap to sales | % | 72.0 | 8.6 | 833.9% | |
Current ratio | x | 4.7 | 1.1 | 405.7% | |
Inventory Days | Days | 6 | 91 | 6.3% | |
Debtors Days | Days | 82 | 96 | 85.6% | |
Net fixed assets | Rs m | 5,246 | 553,293 | 0.9% | |
Share capital | Rs m | 453 | 4,170 | 10.9% | |
Net worth | Rs m | 17,452 | 1,881,695 | 0.9% | |
Long term debt | Rs m | 0 | 866,172 | 0.0% | |
Total assets | Rs m | 22,242 | 3,871,297 | 0.6% | |
Interest coverage | x | 38.0 | 9.8 | 386.6% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.4 | 190.3% | |
Return on assets | % | 12.3 | 3.6 | 343.4% | |
Return on equity | % | 15.2 | 5.6 | 270.3% | |
Return on capital | % | 19.9 | 4.9 | 402.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,374 | 269,933 | 0.9% | |
From Investments | Rs m | -2,592 | -95,648 | 2.7% | |
From Financial Activity | Rs m | 1,978 | -323,803 | -0.6% | |
Net Cashflow | Rs m | 1,760 | -149,518 | -1.2% |
Compare MARKSANS PHARMA. With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare MARKSANS PHARMA. With: PARABOLIC DRUGS ADLINE CHEM LAB HEMO ORGANIC MEDICO REMEDIES SHREE GANESH REMEDIES
Asian stocks inched higher on Tuesday as investors awaited a slew of economic data, corporate earnings and the U.S. Federal Reserve's policy meeting.